Key result
Immunosuppressive therapy improved heart transplantation-free survival compared with standard heart failure therapy alone in patients with inflammatory cardiomyopathy (HR 0.34; 95% CI 0.17-0.92; P=0.043).
Why the study?
Does immunosuppressive therapy improve heart transplantation-free survival and LVEF in patients with virus-negative nonfulminant inflammatory cardiomyopathy?
Population
209 patients with virus-negative nonfulminant inflammatory cardiomyopathy confirmed by endomyocardial biopsy…
Comparison
Immunosuppressive agents added to standard heart… vs Standard heart failure therapy alone
Design
Cohort
Follow-up
median 31 (15-47) months
Authors
Loading...
Immunosuppressive therapy was associated with better survival in inflammatory cardiomyopathy; hypothesis-generating and requires randomized confirmation before practice change.
Cohort (n=209)
Yes
Does immunosuppressive therapy improve heart transplantation-free survival and LVEF in patients with virus-negative nonfulminant inflammatory cardiomyopathy?
Hazard Ratio: 0.34 (95% CI 0.17–0.92)
p-value: p=0.043
Immunosuppressive therapy added to standard heart failure treatment may significantly improve heart transplantation-free survival and left ventricular ejection fraction in patients with virus-negative nonfulminant inflammatory cardiomyopathy.
Merken et al. (2018) conducted a cohort in Virus-Negative Nonfulminant Inflammatory Cardiomyopathy (n=209). Immunosuppressive therapy vs. Standard heart failure therapy alone was evaluated on Heart transplantation-free survival (HR 0.34, 95% CI 0.17-0.92, p=0.043). Immunosuppressive therapy improved heart transplantation-free survival compared with standard heart failure therapy alone in patients with inflammatory cardiomyopathy (HR 0.34; 95% CI 0.17-0.92; P=0.043).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: